NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced eight abstracts were accepted for presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, to be held May 29–31.
“The research being presented displays the broad impact that real-world data derived from electronic health records has across the oncology therapeutic lifecycle from discovery through development and ultimately in support of patient care,” said Dr. Michael Vasconcelles, chief medical officer at Flatiron. “It is a rich illustration of the knowledge that can be created when experts collaborate across the oncology ecosystem.”
The key areas studied include:
- Biomarkers that predict who may benefit from targeted treatments
- Treatment patterns at the end of life
- Barriers and solutions to clinical trial participation
- Novel clinico-genomic research
Flatiron collaborated on the accepted research with: University of Pennsylvania, Yale Cancer Center, Florida Cancer Specialists, Hematology Oncology Associates of Central New York, Southeast Nebraska Cancer Center, Tennessee Oncology, West Cancer Center, Foundation Medicine, and Genentech, a member of the Roche Group.
Full abstracts will be posted at rwe.flatiron.com post-ASCO embargo on May 29.
First Author: Deborah B. Doroshow, Icahn School of Medicine at Mount Sinai
First Author: Emmanuel S. Antonarakis, Sidney Kimmel Comprehensive Cancer Center
First Author: Johnetta Blakely, Tennessee Oncology
First Author: Fauzia Riaz, Yale School of Medicine
First Author: Michael W. Lu, Genentech
First Author: Jeffrey J. Kirshner, Hematology Oncology Associates of Central New York
First Author: Tamara Snow, Flatiron Health
First Author: Sai-Hong I. Ou, University of California Irvine Chao Comprehensive Cancer Center
Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. Our platform enables cancer researchers and care providers to learn from the experience of every patient. Currently, Flatiron partners with over 280 community cancer practices, seven major academic research centers and over 15 of the top therapeutic oncology companies. For more information, please visit www.flatiron.com or follow us @FlatironHealth.
Barbara Rosen, Director of Corporate Communications